Vical Terminates Allovectin Program - Quick Facts

(RTTNews) - Vical Incorporated (VICL) announced that the Phase 3 trial of Allovectin, an investigational intratumoral cancer immunotherapy in patients with metastatic melanoma, has failed to demonstrate a statistically significant improvement in comparison to first-line chemotherapy for either the primary endpoint of objective response rate at 24 weeks or more after randomization or the secondary endpoint of overall survival. Based on the outcome, the company decided to terminate the Allovectin program.

Vijay Samant, President and CEO of Vical, said: "In the coming weeks, we will make the necessary changes to focus resources on our infectious disease vaccine programs and reduce expenses to conserve cash".